Delivery Order SPE2DB22D1041-SPE2DB25FUBC7
- Not listed
- The Defense Logistics Agency awarded a $27,396.14 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,779.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price terms and specifies Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $10,554.18 to AmerisourceBergen Drug Corp for the supply of Ozempic (0.25-0.5 mg/dose) pen injectors in 3 mL formulations. The contract is a firm fixed price delivery order with an ultimate completion date of July 21, 2025, and was awarded on July 18, 2025, without a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for...
- This is a $6,686.04 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens. The award is not set aside and has an ultimate completion date of May 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support...
- The Defense Logistics Agency (DLA) awarded a $1,160.24 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $55,429.15 contract is for the delivery of Ozempic 0.25-0.5 mg/dose pen 3mL, a diabetes medication. The contract has a completion date of May 5, 2025 and is not set aside. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as...
- This is a $9,065.64 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The order has a period of performance through February 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $48,505.54 firm fixed-price contract is for the supply of Ozempic 0.25-0.5 mg/dose pens. It has an ultimate completion date of March 11, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $55,466.72 firm fixed-price contract is for the supply of Ozempic 0.25-0.5 mg/dose pens. The contract has an ultimate completion date of January 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $28,637.28 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division for the provision of Ozempic 0.25-0.5 mg/dose pen 3 mL. This order is part of Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC enables DLA to efficiently procure a comprehensive range of pharmaceutical products and medical...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBC7Delivery Order
The Defense Logistics Agency awarded a $7,252.09 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of July 21, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military healthcare systems globally. This delivery order exemplifies AmerisourceBergen's role within the DLA's Medical Supply Chain, fulfilling federal requirements for diabetes medications and other specialty pharmaceuticals through competitive procurement processes. The company's extensive federal contract portfolio with DLA includes vaccines, brand-name and generic medications, neurological treatments, pain management drugs, and specialized medical supplies across multiple therapeutic domains. The firm fixed-price delivery order structure demonstrates the efficiency of the larger IDC vehicle in enabling rapid fulfillment of specific medical supply needs while maintaining cost predictability for the federal government.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 7/18/25 |